Pre-made Muromonab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-360-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name	Muromonab
Target	CD3E
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2a
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Discontinued
100% SI Structure	1sy6:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	1988
Year Recommended	1989
Companies	Cancer Research UK;Ortho-McNeil;XOMA
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis
Development Tech	na